Posted 7/30/2010 4:20 PM (GMT 0)
HI All,
I'm taking Klair Labs POWDER probiotics. I just had my scope last week and my stool stunk so bad it was terrible! My directions on the bottle says 1/4 tsp (teaspoon) once a day with food. I'm taking 3 TEASPOONS A DAY without food and I feel amazing! My inflammation is down 95%! My stool is so much better, without any bulking agents and the smell is almost gone. I'm able to have stool now that is clean and the water is clear in the toilet, not diarreah that I was having. In the morning my abdomen pain is almost gone! It has taken over a week though to get to this point and taking the probiotics faithfully! I haven't changed my diet. Yesterday was a hamburger and onion rings, and I never eat like that!
I don't know if I was completely cleared out for my scope of all bacteria and reintroduced good bacteria, but things are looking up! I'm still bleeding a little which are my hemmroids I believe. I've ordered two more bottles. I've never tried the powder before, maybe that is helping too, not waiting on a capsules to break open.
My doctor said the Bifiobacterium species live in the last four feet of the large colon as well as reside in the distal end of the small intestine; whereas the Lactobacillus live in the 26 plus feet of the small intestine.
Abstract
Ulcerative colitis (UC) is an acute and chronic inflammatory bowel disease of unknown aetiology, although bacterial species belonging to the normal colonic microbiota are known to be involved in its initiation and maintenance. Several organisms have been linked to the disease; however, mucosa-associated bacteria are more likely to be involved than their luminal counterparts, due to their close proximity to the host epithelium. Comparative bacteriological analyses were done on rectal biopsies to investigate differences in mucosal bacteria in patients with UC and healthy controls. Complex bacterial communities were found in both groups, with significant reductions in bifidobacterial numbers in UC, which suggested that they might have a protective role in the disease. Accordingly, a therapy for treating UC was designed, with the aim of modifying the mucosal microbiota to increase bifidobacterial colonization and reduce inflammation. Ranges of mucosal and faecal bifidobacteria were tested for their substrate preferences and their abilities to survive under a variety of environmental conditions. A synbiotic comprising a probiotic (Bifidobacterium longum) isolated from healthy rectal mucosa combined with a prebiotic (oligofructose-enriched inulin - Synergy 1) was developed. The treatment was used in a randomised controlled trial involving eighteen patients with active UC, for a period of 1 month. Rectal biopsies were collected at the beginning and end of the study. Bacteriological analysis and transcript ion levels of epithelium-related immune markers were assessed. Results demonstrated that short-term synbiotic treatment resulted in increased bifidobacterial colonisation of the rectal mucosa and induced significant reductions in the expression of molecules that control inflammation in active UC.
I will keep you posting.